Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles

Nanotechnology

Volumn 23, Issue 43, 2012, Pages

  Gao, Huile ^a   Yang, Zhi ^a   Cao, Shijie ^a   Xi, Zhangjie ^a   Zhang, Shuang ^a   Pang, Zhiqing ^a   Jiang, Xinguo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUMOR EFFECT; CELLULAR UPTAKE; CRYO-TEM; ENDOSOMES; ENHANCED PERMEATION AND RETENTIONS; IN-VITRO; LAPATINIB; PASSIVE TARGETING; SCAN METHODS; SUB-CELLULAR; SUBCELLULAR LOCALIZATIONS; SURFACE LAYERS; TIME-DEPENDENT; TUMOR SITE;

BIOLOGICAL MATERIALS; IMAGING TECHNIQUES; NANOPARTICLES; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

TUMORS;

ANTINEOPLASTIC AGENT; COUMARIN; COUMARIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; LIPOPROTEIN; NANOPARTICLE; OSTEONECTIN; QUINAZOLINE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; CELL FRACTIONATION; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECT; DRUG SCREENING; ENDOCYTOSIS; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMAN; METABOLISM; MOUSE; NICK END LABELING; NUDE MOUSE; PATHOLOGY; THREE DIMENSIONAL IMAGING; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE, TUMOR; COUMARINS; ENDOCYTOSIS; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; IMAGING, THREE-DIMENSIONAL; IN SITU NICK-END LABELING; LIPOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOPARTICLES; OSTEONECTIN; QUINAZOLINES; RECEPTOR, ERBB-2; SUBCELLULAR FRACTIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867448130     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/23/43/435101     Document Type: Article

References (27)

1. Liu Y and Lu W 2012 Recent advances in brain tumor-targeted nano-drug delivery systems Expert Opin. Drug Discov. 9 67186
2. Serwer L P and James C D 2012 Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations Adv. Drug Deliv. Rev. 64 5907
3. Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X and Zhang Q 2012 Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles Biomaterials 33 511523
4. Brannon-Peppas L and Blanchette J O 2004 Nanoparticle and targeted systems for cancer therapy Adv. Drug Deliv. Rev. 56 164959 (Pubitemid 39177694)
5. Xia W, Gerard C M, Liu L, Baudson N M, Ory T L and Spector N L 2005 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells Oncogene 24 621321 (Pubitemid 43080044)
6. Giannopoulou E, Dimitropoulos K, Argyriou A, Koutras A, Dimitrakopoulos F and Kalofonos H 2010 An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines Investig. New Drugs 28 554
7. Fu Q, Sun J, Zhang W, Sui X, Yan Z and He Z 2009 Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery Recent Pat. Anticancer Drug Discov. 4 26272
8. Kratz F 2008 Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 17183
9. Medina P J and Goodin S 2008 Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 30 142647
10. Nagane M, Pan G, Weddle J J, Dixit V M, Cavenee W K and Huang H J 2000 Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo Cancer Res. 60 84753 (Pubitemid 30129513)
11. Thiessen B et al 2010 A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation Cancer Chemother. Pharmacol. 65 35361
12. Maeda H 2001 SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy Adv. Drug Deliv. Rev. 46 16985
13. Matsumura Y and Maeda H 1986 A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS Cancer Res. 46 638792 (Pubitemid 17221789)
14. Torchilin V P 2010 Passive and active drug targeting: drug delivery to tumors as an example Handb. Exp. Pharmacol. 197 353
15. Fang J, Sawa T and Maeda H 2003 Factors and mechanism of EPR effect and the enhanced antitumor effects of macromolecular drugs including SMANCS Adv. Exp. Med. Biol. 519 2949 (Pubitemid 36577698)
16. Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S, Jiang X and Zhang P 2010 Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats Mol. Pharmacol. 7 19952005
17. Zhan C, Gu B, Xie C, Li J, Liu Y and Lu W 2010 Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect J. Control. Release 143 13642
18. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, Gao X, Jiang X and Zhu C 2008 Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26 J. Control. Release 128 1207
19. Heikkila J E, Vaha-Koskela M J, Ruotsalainen J J, Martikainen M W, Stanford M M, McCart J A, Bell J C and Hinkkanen A E 2010 Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice PLoS One 5 e8603
20. Gorlick R et al 2009 Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program Pediatr. Blood Cancer 53 5948
21. Perrault S D, Walkey C, Jennings T, Fischer H C and Chan W C 2009 Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 190915
22. Yuan F, Dellian M, Fukumura D, Leunig M, Berk D A, Torchilin V P and Jain R K 1995 Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 37526
23. Ding H et al 2011 Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers Nanotechnology 22 165101
24. Desai N P, Trieu V, Hwang L Y, Wu R, Soon-Shiong P and Gradishar W J 2008 Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status Anticancer Drugs 19 899909
25. Rusnak D W et al 2001 The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer Cancer Res. 61 7196203 (Pubitemid 32946515)
26. Wainberg Z A, Anghel A, Desai A J, Ayala R, Luo T, Safran B, Fejzo M S, Hecht J R, Slamon D J and Finn R S 2010 Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo Clin. Cancer Res. 16 150919
27. Sambade M J, Kimple R J, Camp J T, Peters E, Livasy C A, Sartor C I and Shields J M 2010 Lapatinib in combination with radiation diminishes tumor regrowth in HER2 + and basal-like/EGFR + breast tumor xenografts Int. J. Radiat. Oncol. Biol. Phys. 77 57581